Abstract: Objective To investigate the clinical effect of recombinant human erythropoietin combined with iron sucrose in treatment of anemia patients with maintenance hemodialysis. Methods Totally 64 anemia patients with maintenance hemodialysis were selected and randomly divided into control group and observation group, with 32 cases in each group. The control group was treated with iron sucrose, while the observation group was treated with recombinant human erythropoietin on the basis of the control group. Both groups were treated for 8 weeks. The clinical effect, the red blood cell parameters, iron metabolism indexes and inflammation indexes before and after treatment as well as adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 84.38%, which was significantly higher than 65.63% of the control group(P<0.05). After treatment, levels of hematocrit(Hct), hemoglobin(Hb), transferrin saturation(TSAT)and ferritin(SF)in both groups were significantly higher than those before treatment, and the indexes mentioned above in the observation group were significantly higher than those in the control group(P<0.05). After treatment, the levels of tumor necrosis factor-α(TNF-α), interleukin-6(IL-6)and high sensitivity C-reactive protein(hs-CRP)in the observation group were significantly lower than those in the control group(P<0.05). No obvious adverse reactions were found in both groups during the treatment. Conclusion Recombinant human erythropoietin combined with iron sucrose is effective in treatment of anemia patients with maintenance hemodialysis, which can improve the iron metabolism of patients, promote the metabolism of red blood cells, and reduce the levels of - inflammatory factors.